These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32296414)

  • 1. Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma.
    Hansen HP; Paes Leme AF; Hallek M
    Front Immunol; 2020; 11():398. PubMed ID: 32296414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.
    Hansen HP; Trad A; Dams M; Zigrino P; Moss M; Tator M; Schön G; Grenzi PC; Bachurski D; Aquino B; Dürkop H; Reiners KS; von Bergwelt-Baildon M; Hallek M; Grötzinger J; Engert A; Paes Leme AF; Pogge von Strandmann E
    Oncotarget; 2016 May; 7(21):30523-35. PubMed ID: 27105521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.
    Hansen HP; Engels HM; Dams M; Paes Leme AF; Pauletti BA; Simhadri VL; Dürkop H; Reiners KS; Barnert S; Engert A; Schubert R; Quondamatteo F; Hallek M; Pogge von Strandmann E
    J Pathol; 2014 Mar; 232(4):405-14. PubMed ID: 24659185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin.
    Lobastova L; Lettau M; Babatz F; de Oliveira TD; Nguyen PH; Pauletti BA; Schauss AC; Dürkop H; Janssen O; Paes Leme AF; Hallek M; Hansen HP
    Front Cell Dev Biol; 2021; 9():698503. PubMed ID: 34395429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
    Rinaldi I
    Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of ADAM10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.
    Pece R; Tavella S; Costa D; Varesano S; Camodeca C; Cuffaro D; Nuti E; Rossello A; Alfano M; D'Arrigo C; Galante D; Ravetti JL; Gobbi M; Tosetti F; Poggi A; Zocchi MR
    Haematologica; 2022 Apr; 107(4):909-920. PubMed ID: 34109776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells.
    Tosetti F; Venè R; Camodeca C; Nuti E; Rossello A; D'Arrigo C; Galante D; Ferrari N; Poggi A; Zocchi MR
    Oncoimmunology; 2018; 7(5):e1421889. PubMed ID: 29721369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.
    van der Weyden CA; Pileri SA; Feldman AL; Whisstock J; Prince HM
    Blood Cancer J; 2017 Sep; 7(9):e603. PubMed ID: 28885612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).
    Horn-Lohrens O; Tiemann M; Lange H; Kobarg J; Hafner M; Hansen H; Sterry W; Parwaresch RM; Lemke H
    Int J Cancer; 1995 Feb; 60(4):539-44. PubMed ID: 7530238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro.
    Eichenauer DA; Simhadri VL; von Strandmann EP; Ludwig A; Matthews V; Reiners KS; von Tresckow B; Saftig P; Rose-John S; Engert A; Hansen HP
    Cancer Res; 2007 Jan; 67(1):332-8. PubMed ID: 17210715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
    Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
    Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD30: an important new target in hematologic malignancies.
    Deutsch YE; Tadmor T; Podack ER; Rosenblatt JD
    Leuk Lymphoma; 2011 Sep; 52(9):1641-54. PubMed ID: 21619423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
    Gruss H-J ; Herrmann F
    Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
    Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
    J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment.
    Ferrarini I; Rigo A; Zamò A; Vinante F
    Leuk Lymphoma; 2019 Dec; 60(14):3395-3405. PubMed ID: 31304817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin.
    Hansen HP; Matthey B; Barth S; Kisseleva T; Mokros T; Davies SJ; Beckett RP; Foelster-Holst R; Lange HH; Engert A; Lemke H
    Int J Cancer; 2002 Mar; 98(2):210-5. PubMed ID: 11857410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy in relapsed classical hodgkin lymphoma.
    Dinner S; Advani R
    J Natl Compr Canc Netw; 2013 Aug; 11(8):968-76. PubMed ID: 23946175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
    Bhatt G; Maddocks K; Christian B
    Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D connectomes of reactive and neoplastic CD30 positive lymphoid cells and surrounding cell types.
    Lumer L; Wurzel P; Scharf S; Schäfer H; Ackermann J; Koch I; Hansmann ML
    Acta Histochem; 2021 Jul; 123(5):151750. PubMed ID: 34233254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.